Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

Cali Biosciences Co., Ltd. announced it has initiated Phase III studies of its core product, CPL-01, with dosing in hernia patients already begun and dosing in bunion patients scheduled to start next month.